TransCode Therapeutics (RNAZ) Cash Flow: Operating & Free Cash Flow

TransCode Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for TransCode Therapeutics, Inc. (RNAZ) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-34.66	-16.75	-18.55	-18.55	-17.56	-6.84	-6.84	-2.34	-0.61	-0.45
Depreciation & Amortization	0.11	0.53	0.52	0.52	0.10	0.04	0.04	0.00	0.00	0.00
Deferred Income Tax	0.00	0.00	0.00	-	0.00	0.88	-	0.00	0.00	0.00
Stock Based Compensation	0.49	1.70	0.00	1.04	0.40	0.19	0.19	0.05	0.00	0.02
Change in Working Capital	0.02	-0.35	-1.08	-1.08	1.31	0.43	0.43	0.31	0.00	0.02
Change in Accounts Receivable	-0.95	0.00	0.36	-	-0.36	0.00	-	0.00	0.00	0.00
Change in Accounts Payable	0.00	0.00	-1.30	-1.30	1.84	2.29	2.29	0.19	-0.05	0.00
Change in Other Working Capital	0.02	-0.35	-0.15	-1.08	1.31	-1.85	0.43	0.12	0.05	0.02
Other Operating Activities	14.53	1.54	1.04	-	0.00	0.04	0.92	1.50	0.10	0.11
Net Cash from Operating Activities	-19.52	-13.34	-18.07	-18.07	-15.76	-5.27	-5.27	-0.49	-0.51	-0.30
Investing Activities
Capital Expenditures	-0.01	-0.02	-0.04	-0.04	-0.10	-0.25	-0.25	0.00	0.00	0.00
Acquisitions	0.00	0.00	0.00	-	0.00	0.00	-	0.00	0.00	0.00
Other Investing Activities	0.00	0.00	0.00	-	0.00	0.00	-	0.00	0.00	0.00
Net Cash from Investing Activities	0.00	-0.02	-0.04	-0.04	-0.10	-0.25	-0.25	0.00	0.00	0.00
Financing Activities
Debt Repayment	0.00	0.00	0.00	-	0.00	0.00	-	1.19	0.50	0.55
Common Stock Issued	8.85	16.40	15.91	15.91	0.01	26.34	26.38	0.00	0.00	0.00
Other Financing Activities	22.67	0.00	0.00	-	0.00	-0.82	-0.86	-0.07	0.00	-0.04
Net Cash from Financing Activities	31.52	16.40	15.91	15.91	0.01	25.52	25.52	1.12	0.50	0.51
Summary
Net Change in Cash	12.00	3.04	-2.20	-2.20	-15.86	20.00	20.00	0.62	-0.01	0.21
Cash at Beginning of Period	5.81	2.77	4.97	4.97	20.83	0.83	0.83	0.20	0.21	0.00
Cash at End of Period	17.81	5.81	2.77	2.77	4.97	20.83	20.83	0.83	0.20	0.21
Free Cash Flow	-19.52	-13.36	-18.11	-18.11	-15.86	-5.52	-5.52	-0.49	-0.51	-0.30
Supplemental Disclosures
Interest Paid	-	0.02	-	0.03	0.04	-	0.02	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TransCode Therapeutics Cash Flow

What is TransCode Therapeutics's free cash flow?

TransCode Therapeutics had negative free cash flow of $19.52M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$19.52M minus $6.66K of capital expenditures.

How much does TransCode Therapeutics spend on capital expenditures?

TransCode Therapeutics spent $6.66K on capital expenditures in fiscal 2025, compared with $21.76K a year earlier.

Does TransCode Therapeutics pay dividends or buy back shares?

TransCode Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition